Clinical Trials on Meningococcal Disease

Total 381502 results

GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Infections, Meningococcal

Mexico, Argentina
GlaxoSmithKline

Completed

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants

Infections, Meningococcal
Sanofi Pasteur, a Sanofi Company

Completed

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Meningitis | Meningococcal Disease

United States
The Immunobiological Technology Institute (Bio-Manguinhos)...

Unknown

Conjugate Vaccine Against Meningococcus C a Brazilian Project

Serogroup C Meningococcal Meningitis

Brazil
Novartis
Novartis Vaccines

Completed

Persistence of Immune Response After Vaccination With MCC

Prevention of Meningococcal Infection

United Kingdom
Novartis Vaccines

Completed

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Prevention of Meningococcal Infection

Germany, Poland
London School of Hygiene and Tropical Medicine
Public Health England; Stanford University; World Health Organization; University... and other collaborators

Unknown

Maternal Immunization With MenAfriVac™

Meningitis | Meningococcal

Gambia
Public Health England

Withdrawn

Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock (Lock and Key)

Meningitis

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children

Meningitis | Meningococcal Disease

China
GlaxoSmithKline

Completed

Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers

Infections, Meningococcal
Sanofi Pasteur, a Sanofi Company

Completed

Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

Meningitis | Meningococcal Infection

Canada
Novartis Vaccines
GlaxoSmithKline

Completed

Persistence of Antibody Response to N. Meningitidis Group C in Children

Prevention of Meningococcal Infection

Spain, Poland
Novartis Vaccines

Completed

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Prevention of Meningococcal Infection

United Kingdom
Novartis
Novartis Vaccines

Completed

Kinetics of B Cell Response in Infants Menjugate Vaccination

Prevention of Meningococcal Infection

United Kingdom
JN-International Medical Corporation

Completed

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation

Meningitis | Meningococcal Infection

Russian Federation, India
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Meningitis | Meningococcal Infection

United States
Novartis
Novartis Vaccines

Completed

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Meningitis | Meningococcal Infection

United States, China, Costa Rica, Guatemala, Panama, Peru
Novartis Vaccines
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Hepatitis B | Hepatitis A | Meningococcal Disease | Meningococcal Meningitis

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Meningitis | Meningococcal Infection

United States
Centro Superior de Investigación en Salud Publica

Completed

Immunogenicity of the Booster Dose of Two MenC Vaccines (CSISP-MENC1)

Meningococcal Infection

Spain
Sanofi

Completed

A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India

Meningitis | Meningococcal Infection

India
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Dose Comparison Study of Menactra® in US Children

Meningitis | Meningococcal Infection | Neisseria Meningitidis

United States
Novartis
Novartis Vaccines

Completed

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Meningococcal Meningitis

United States, Italy
University of Oxford

Completed

Investigating Meningococcal Vaccines in Adults

Meningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria Meningitidi

United Kingdom
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Prevention of Meningococcal Infection

Italy
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Thailand, Estonia, Dominican Republic
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

Infections, Meningococcal

Germany, Korea, Republic of, Dominican Republic
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infection

Australia
GlaxoSmithKline

Completed

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Infections, Meningococcal

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

Meningitis | Meningococcal Disease

Korea, Republic of
GlaxoSmithKline

Completed

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Infections, Meningococcal

South Africa
University of Adelaide

Completed

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults (AMEND)

Meningococcal Infections | Neisseria Infection | Neisseria Meningitis Sepsis

Australia
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Meningococcal Sero-type C Infection

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

Meningitis | Meningococcal Infection

United States
University of Oxford

Completed

Understanding the Immune Response to Two Different Meningitis Vaccines

Meningitis | Meningococcal Disease | Septicaemia

United Kingdom
University of California, Los Angeles
Centers for Disease Control and Prevention

Completed

Testing the Use of Prompts to Increase Adolescent Immunization Rates (AIMHi)

Pertussis | Influenza | Human Papillomavirus | Meningococcal Disease | Vaccine Preventable Diseases

United States
St George's, University of London
GlaxoSmithKline; Public Health England; MeningitisNow

Completed

Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B (BEAR Men B)

Prematurity | Meningococcal Disease | Vaccination

United Kingdom
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
University Hospital Southampton NHS Foundation...
University of Southampton

Unknown

A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14 (Lac-3)

Meningitis, Meningococcal

United Kingdom
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guangxi Center for Disease Control... and other collaborators

Unknown

Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Meningitis, Meningococcal

China
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden

Clinical Trials on Meningococcal Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations